본문 바로가기
KERD
논문KCI 등재

Blood pressure control in patients with chronic kidney disease

Seung Hyeok Han|Jee Young Lee
대한내과학회 (The Korean Association Of Internal Medicine)|2021.07|The Korean Journal of Internal Medicine|제36권 제4호|pp. 780-794|DOI https://doi.org/10.3904/kjim.2021.181

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Blood pressureRenal insufficiencychronicChronic renal insufficiency
주제분류내과학

초록

Uncontrolled blood pressure (BP) in patients with chronic kidney disease (CKD) can lead to serious adverse outcomes. To prevent the occurrence of cardiovascular events (CVEs), and end-stage kidney disease, achieving an optimal BP level is important. Recently, there has been a paradigm shift in the management of BP largely as a result of the Systolic Blood Pressure Intervention Trial (SPRINT), which showed a reduction in CVEs by lowering systolic BP to 120 mmHg. A lower systolic blood pressure (SBP) target has been accepted by the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines. However, whether intensive control of SBP targeting < 120 mmHg is also effective in patients with CKD is controversial. Notably, this lower target SBP is associated with a higher risk of adverse kidney outcomes. Unfortunately, there have been no randomized controlled trials on this issue involving only patients with CKD, particularly those with advanced CKD. In this review, we discuss the optimal control of BP in patients with CKD in terms of reduction in death and CVEs as well as attenuation of CKD progression based on the evidence-based literature.

Abstract

Uncontrolled blood pressure (BP) in patients with chronic kidney disease (CKD) can lead to serious adverse outcomes. To prevent the occurrence of cardiovascular events (CVEs), and end-stage kidney disease, achieving an optimal BP level is important. Recently, there has been a paradigm shift in the management of BP largely as a result of the Systolic Blood Pressure Intervention Trial (SPRINT), which showed a reduction in CVEs by lowering systolic BP to 120 mmHg. A lower systolic blood pressure (SBP) target has been accepted by the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines. However, whether intensive control of SBP targeting < 120 mmHg is also effective in patients with CKD is controversial. Notably, this lower target SBP is associated with a higher risk of adverse kidney outcomes. Unfortunately, there have been no randomized controlled trials on this issue involving only patients with CKD, particularly those with advanced CKD. In this review, we discuss the optimal control of BP in patients with CKD in terms of reduction in death and CVEs as well as attenuation of CKD progression based on the evidence-based literature.

참고문헌 (93)

  1. Oh Kook-Hwan, "The KNOW-CKD Study: What we have learned about chronic kidney diseases", Kidney Research and Clinical Practice, 39(2), pp.121~135 (2020), 대한신장학회[DOI]
  2. 손형은, "Association of ambulatory blood pressure monitoring with renal outcome in patients with chronic kidney disease", Kidney Research and Clinical Practice, 39(1), pp.70~80 (2020), 대한신장학회[DOI]
  3. Shahrokh Ezzatzadegan Jahromi, "Comparisons between different blood pressure measurement techniques in patients with chronic kidney disease", Kidney Research and Clinical Practice, 38(2), pp.212~219 (2019), 대한신장학회[DOI]
  4. Kipyo Kim, "Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea", The Korean Journal of Internal Medicine, 35(5), pp.1173~1187 (2020), 대한내과학회[DOI]
  5. 김형래, "Baseline Cardiovascular Characteristics of Adult Patients with Chronic Kidney Disease from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)", Journal of Korean Medical Science, 32(2), pp.231~239 (2017), 대한의학회
  6. Jha V, "Getting to know the enemy better-the global burden of chronic kidney disease", Kidney Int, 94, pp.462~464 (2018)
  7. 김경민, "Impact of chronic kidney disease on mortality: A nationwide cohort study", Kidney Research and Clinical Practice, 38(3), pp.382~390 (2019), 대한신장학회[DOI]
  8. 백선하, "Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease", The Korean Journal of Internal Medicine, 34(4), pp.858~866 (2019), 대한내과학회[DOI]
  9. 이창현, "Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study", Kidney Research and Clinical Practice, 38(1), pp.49~59 (2019), 대한신장학회[DOI]
  10. 박성하, "Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure", The Korean Journal of Internal Medicine, 34(1), pp.44~49 (2019), 대한내과학회[DOI]
  11. Obermayr RP, "Predictors of new-onset decline in kidney function in a general middle-european population", Nephrol Dial Transplant, 23, pp.1265~1273 (2008)
  12. Reynolds K, "A population-based, prospective study of blood pressure and risk for end-stage renal disease in China", J Am Soc Nephrol, 18, pp.1928~1935 (2007)
  13. Xue H, "Prehypertension and chronic kidney disease in chinese population : four-year follow-up study", PLoS One, 10, pp.e0144438~ (2015)
  14. Garofalo C, "Hypertension and prehypertension and prediction of development of decreased estimated GFR in the general population : a meta-analysis of cohort studies", Am J Kidney Dis, 67, pp.89~97 (2016)
  15. Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61prospective studies", Lancet, 360, pp.1903~1913 (2002)
  16. Colantonio LD, "2017 ACC", AHA blood pressure treatment guideline recommendations and cardiovascular risk, 2018, pp.72, 1187~1197
  17. Mancia G, "2013 ESH", ESC guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.34, 2159~2219
  18. James PA, "2014 Evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee(JNC 8)", JAMA, 311, pp.507~520 (2014)
  19. Jaques H, "NICE guideline on hypertension", Eur Heart J, 34, pp.406~408 (2013)
  20. Weber MA, "Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension", J Hypertens, 32, pp.3~15 (2014)
  21. Eknoyan G, "KDIGO 2012clinical practice guideline for the evaluation and management of chronic kidney disease : summary of recommendation statements", Kidney Int Suppl, 3, pp.5~14 (2013)
  22. Rabi DM, "Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children", Can J Cardiol, 36, pp.596~624 (2020)
  23. Becker GJ, "KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int Suppl, 2, pp.337~414 (2012)
  24. SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
  25. Kidney Disease : Improving Global Outcomes(KDIGO)Blood Pressure Work Group, "KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int, 99, pp.S1~ (2021)
  26. ACCORD Study Group, "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
  27. Lonn EM, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
  28. Ruggenenti P, "Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease(REIN-2) : multicentre, randomised controlled trial", Lancet, 365, pp.939~946 (2005)
  29. Cuspidi C, "Treatment of hypertension : the ESH", ESC guidelines recommendations, 2018, pp.128, 315~321
  30. Pilmore H, "Cardiovascular disease in patients with chronic kidney disease", Nephrology (Carlton), 19, pp.3~10 (2014)
  31. Prichard S, "Clinical practice guidelines of the Canadian Society of Nephrology for the treatment of patients with chronic renal failure : a re-examination", Contrib Nephrol, 140, pp.163~169 (2003)
  32. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
  33. Unger T, "2020 International Society of Hypertension global hypertension practice guidelines", J Hypertens, 38, pp.982~1004 (2020)
  34. Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension : the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, 2018, pp.36, 1953~2041
  35. Flack JM, "Management of high blood pressure in Blacks : an update of the International Society on Hypertension in Blacks consensus statement", Hypertension, 56, pp.780~800 (2010)
  36. Ahmad FS, "Validity of cardiovascular data from electronic sources : the multi-ethnic study of atherosclerosis and HealthLNK", Circulation, 136, pp.1207~1216 (2017)
  37. Cheung AK, "Effects of intensive BP control in CKD", J Am Soc Nephrol, 28, pp.2812~2823 (2017)
  38. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
  39. Aggarwal R, "Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients", Hypertension, 73, pp.1275~1282 (2019)
  40. Malhotra R, "Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5 : a systematic review and meta-analysis", JAMA Intern Med, 177, pp.1498~1505 (2017)
  41. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38", BMJ, 317, pp.703~713 (1998)
  42. Hansson L, "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group", Lancet, 351, pp.1755~1762 (1998)
  43. Berl T, "Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial", J Am Soc Nephrol, 16, pp.2170~2179 (2005)
  44. Kovesdy CP, "Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease", JAMA Intern Med, 174, pp.1442~1449 (2014)
  45. Sim JJ, "Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population", J Am Coll Cardiol, 64, pp.588~597 (2014)
  46. Navaneethan SD, "Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease", Kidney Int, 92, pp.1272~1281 (2017)
  47. Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
  48. de Galan BE, "Lowering blood pressure reduces renal events in type 2 diabetes", J Am Soc Nephrol, 20, pp.883~892 (2009)
  49. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387, pp.435~443 (2016)
  50. Nadkarni GN, "Effect of intensive blood pressure lowering on kidney tubule injury : findings from the ACCORD Trial Study participants", Am J Kidney Dis, 73, pp.31~38 (2019)
  51. Rocco MV, "Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial(SPRINT)", Am J Kidney Dis, 71, pp.352~361 (2018)
  52. Heerspink HJL, "Change in albuminuria as a surrogate endpoint for progression of kidney disease : a meta-analysis of treatment effects in randomised clinical trials", Lancet Diabetes Endocrinol, 7, pp.128~139 (2019)
  53. Levey AS, "Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency", Am J Kidney Dis, 75, pp.84~104 (2020)
  54. Hsu CY, "Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease", Arch Intern Med, 165, pp.923~928 (2005)
  55. Schaeffner ES, "Blood pressure measures and risk of chronic kidney disease in men", Nephrol Dial Transplant, 23, pp.1246~1251 (2008)
  56. Chang TI, "Associations of systolic blood pressure with incident CKD G3-G5 : a cohort study of South Korean adults", Am J Kidney Dis, 76, pp.224~232 (2020)
  57. Joo YS, "Association of longitudinal trajectories of systolic BP with risk of incident CKD : results from the Korean Genome and Epidemiology Study", J Am Soc Nephrol, 31, pp.2133~2144 (2020)
  58. Appel LJ, "Intensive blood-pressure control in hypertensive chronic kidney disease", N Engl J Med, 363, pp.918~929 (2010)
  59. Klahr S, "The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group", N Engl J Med, 330, pp.877~884 (1994)
  60. Sarnak MJ, "The effect of a lower target blood pressure on the progression of kidney disease : long-term follow-up of the modification of diet in renal disease study", Ann Intern Med, 142, pp.342~351 (2005)
  61. Tsai WC, "Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease : a systematic review and meta-analysis", JAMA Intern Med, 177, pp.792~799 (2017)
  62. Lv J, "Effects of intensive blood pressure lowering on the progression of chronic kidney disease : a systematic review and meta-analysis", CMAJ, 185, pp.949~957 (2013)
  63. Curb JD, "Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group", JAMA, 276, pp.1886~1892 (1996)
  64. Tuomilehto J, "Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators", N Engl J Med, 340, pp.677~684 (1999)
  65. Schrier RW, "Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes", Kidney Int, 61, pp.1086~1097 (2002)
  66. Bakris GL, "Effects of blood pressure level on progression of diabetic nephropathy : results from the RENAAL study", Arch Intern Med, 163, pp.1555~1565 (2003)
  67. Pohl MA, "Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial : clinical implications and limitations", J Am Soc Nephrol, 16, pp.3027~3037 (2005)
  68. Lewis EJ, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group", N Engl J Med, 329, pp.1456~1462 (1993)
  69. Agodoa LY, "Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis : a randomized controlled trial", JAMA, 285, pp.2719~2728 (2001)
  70. Lewis EJ, "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
  71. Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
  72. Ruggenenti P, "Preventing microalbuminuria in type 2 diabetes", N Engl J Med, 351, pp.1941~1951 (2004)
  73. Gerstein HC, "Dulaglutide and renal outcomes in type 2 diabetes : an exploratory analysis of the REWIND randomised, placebo-controlled trial", Lancet, 394, pp.131~138 (2019)
  74. Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy", N Engl J Med, 380, pp.2295~2306 (2019)
  75. Davies MJ, "Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", Diabetes Care, 41, pp.2669~2701 (2018)
  76. Kidney Disease : Improving Global Outcomes(KDIGO)Diabetes Work Group, "KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease", Kidney Int, 98, pp.S1~ (2020)
  77. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
  78. Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes", N Engl J Med, 375, pp.323~334 (2016)
  79. Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
  80. Heerspink HJL, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
  81. Wang B, "Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide : a meta-analysis of clinical trials", Diabetes Obes Metab, 15, pp.737~749 (2013)
  82. Majewski C, "Blood pressure reduction : an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes", Diabetes Care, 38, pp.429~430 (2015)
  83. Kohan DE, "Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy", J Am Soc Nephrol, 22, pp.763~772 (2011)
  84. Heerspink HJL, "Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease(SONAR) : a double-blind, randomised, placebo-controlled trial", Lancet, 393, pp.1937~1947 (2019)
  85. Trachtman H, "DUET : a phase 2study evaluating the efficacy and safety of sparsentan in patients with FSGS", J Am Soc Nephrol, 29, pp.2745~2754 (2018)
  86. Raichlin E, "Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis", Hypertension, 52, pp.522~528 (2008)
  87. Bianchi S, "Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease", Kidney Int, 70, pp.2116~2123 (2006)
  88. Pitt B, "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", N Engl J Med, 341, pp.709~717 (1999)
  89. Pitt B, "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction", N Engl J Med, 348, pp.1309~1321 (2003)
  90. Williams B, "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY-2) : a randomised, double-blind, crossover trial", Lancet, 386, pp.2059~2068 (2015)
  91. Krieger EM, "Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension : the ReHOT Randomized Study(Resistant Hypertension Optimal Treatment)", Hypertension, 71, pp.681~690 (2018)
  92. Bakris GL, "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", N Engl J Med, 383, pp.2219~2229 (2020)
  93. Mosenzon O, "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes : an analysis from the DECLARE-TIMI 58 randomised trial", Lancet Diabetes Endocrinol, 7, pp.606~617 (2019)

관련 논문AI추천

Optimal blood pressure target and measurement in patients with chronic kidney disease김수완, 김창성, 마성권, 배은희, 최홍상대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제6호Diagnosis and treatment of hypertension in dialysis patients: a systematic reviewKim In Soo, Kim Jwa-Kyung, Kim Sungmin, Yoo Tae-Hyun대한고혈압학회 · Clinical Hypertension2023 · 제29권 신기능 저하가 있는 노인환자에서 고혈압의 치료: 혈압목표의 설정과 약제선택에 대한 최근의 쟁점들을 중심으로김문재대한고혈압학회 · Clinical Hypertension2011 · 제17권 제4호Short-term blood pressure variability as a potential therapeutic target for kidney diseaseJhee Jong Hyun, Ko Ye Eun대한고혈압학회 · Clinical Hypertension2023 · 제29권 Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial홍순준, Han Byoung-Geun, Han Sang Youb, Hur Kyu Yeon, Kang Young Sun, Kim Dong Ki, Kim Sung Gyun, Kim Yong-Jin, Lee Jung Pyo, Lee Sangho, Na Ki-Ryang, Park Cheol Ho, Park Jongha, Park Sungha, Shin Seok Joon, Won Jong Chul, Yoo Tae-Hyun대한고혈압학회 · Clinical Hypertension2024 · 제30권 Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease고은실, 정성진, Jo Wonji대한고혈압학회 · Clinical Hypertension2023 · 제29권

이 간행물의 다른 논문 (28건)

The role of inflammation in diabetic kidney diseaseJu-Young Moon, Su Woong Jungpp. 753-766Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patientsKook-Hwan Oh, 박혜인, Yong-Chul Kim, Yun Kyu Oh, Hyunjin Ryupp. 767-779How important is dietary management in chronic kidney disease progression? A role for low protein dietsGang-Jee Ko, Kamyar Kalantar-Zadehpp. 795-806Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020Il Ju Choi, Jae Gyu Kim, Seon-Young Park, Hye-Kyung Jung, Woon Geon Shin, Hyo-Joon Yang, 김지현, 임현철, 이용찬, Sung Eun Kim, Jae Myung Park, Miyoung Choi, Su Youn Nam, Seung Joo Kang, Cheol Min Shinpp. 807-838Risk-stratified colorectal cancer screening for optimal use of colonoscopy resourcesDong-Hoon Yangpp. 839-841
원문 보기